| The major genetic determinants of HIV-1 control affect HLA class I peptide presentation International HIV Controllers Study Science 330 (6010), 1551-1557, 2010 | 1109 | 2010 |
| British HIV Association guidelines for the treatment of HIV‐1‐positive adults with antiretroviral therapy 2012 (Updated November 2013. All changed text is cast in yellow … Writing Group, I Williams, D Churchill, J Anderson, M Boffito, M Bower, ... HIV medicine 15, 1-6, 2014 | 419 | 2014 |
| Controversies in HIV-associated neurocognitive disorders S Nightingale, A Winston, S Letendre, BD Michael, JC McArthur, S Khoo, ... The Lancet Neurology 13 (11), 1139-1151, 2014 | 332 | 2014 |
| Assessment, diagnosis, and treatment of HIV-associated neurocognitive disorder: a consensus report of the mind exchange program Mind Exchange Working Group, A Antinori, G Arendt, I Grant, S Letendre, ... Clinical Infectious Diseases 56 (7), 1004-1017, 2013 | 223 | 2013 |
| Increased brain-predicted aging in treated HIV disease JH Cole, J Underwood, MWA Caan, D De Francesco, RA Van Zoest, ... Neurology 88 (14), 1349-1357, 2017 | 220 | 2017 |
| Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 in HIV infection: a single-arm substudy of a phase 2/3 clinical trial J Frater, KJ Ewer, A Ogbe, M Pace, S Adele, E Adland, J Alagaratnam, ... The lancet HIV 8 (8), e474-e485, 2021 | 216 | 2021 |
| Effects of hydroxychloroquine on immune activation and disease progression among HIV-infected patients not receiving antiretroviral therapy: a randomized controlled trial NI Paton, RL Goodall, DT Dunn, S Franzen, Y Collaco-Moraes, ... Jama 308 (4), 353-361, 2012 | 181 | 2012 |
| Increased microglia activation in neurologically asymptomatic HIV-infected patients receiving effective ART LJ Garvey, N Pavese, M Politis, A Ramlackhansingh, DJ Brooks, ... Aids 28 (1), 67-72, 2014 | 176 | 2014 |
| Neuroinflammation in treated HIV-positive individuals: a TSPO PET study JH Vera, Q Guo, JH Cole, A Boasso, L Greathead, P Kelleher, EA Rabiner, ... Neurology 86 (15), 1425-1432, 2016 | 165 | 2016 |
| Factors influencing efavirenz and nevirapine plasma concentration: effect of ethnicity, weight and co-medication W Stöhr, D Back, D Dunn, C Sabin, A Winston, R Gilson, D Pillay, T Hill, ... Antiviral therapy 13 (5), 675-685, 2008 | 158 | 2008 |
| Antiretroviral penetration into the CNS and incidence of AIDS-defining neurologic conditions EC Caniglia, LE Cain, A Justice, J Tate, R Logan, C Sabin, A Winston, ... Neurology 83 (2), 134-141, 2014 | 156 | 2014 |
| 2019 update of the European AIDS Clinical Society Guidelines for treatment of people living with HIV version 10.0 L Ryom, A Cotter, R De Miguel, C Béguelin, D Podlekareva, JR Arribas, ... HIV medicine 21 (10), 617-624, 2020 | 155 | 2020 |
| Could antiretroviral neurotoxicity play a role in the pathogenesis of cognitive impairment in treated HIV disease? J Underwood, KR Robertson, A Winston Aids 29 (3), 253-261, 2015 | 147 | 2015 |
| Transmission of monkeypox virus through sexual contact–A novel route of infection J Heskin, A Belfield, C Milne, N Brown, Y Walters, C Scott, M Bracchi, ... Journal of Infection 85 (3), 334-363, 2022 | 144 | 2022 |
| Incomplete reversibility of estimated glomerular filtration rate decline following tenofovir disoproxil fumarate exposure S Jose, L Hamzah, LJ Campbell, T Hill, M Fisher, C Leen, R Gilson, ... The Journal of infectious diseases 210 (3), 363-373, 2014 | 132 | 2014 |
| HIV‐associated central nervous system diseases in the recent combination antiretroviral therapy era UK Collaborative HIV Cohort (CHIC) Study Steering Committee European journal of neurology 18 (3), 527-534, 2011 | 128 | 2011 |
| Psychiatric symptoms in patients receiving dolutegravir A Fettiplace, C Stainsby, A Winston, N Givens, S Puccini, V Vannappagari, ... JAIDS Journal of Acquired Immune Deficiency Syndromes 74 (4), 423-431, 2017 | 123 | 2017 |
| Minor changes in calculated creatinine clearance and anion‐gap are associated with tenofovir disoproxil fumarate‐containing highly active antiretroviral therapy A Winston, J Amin, PWG Mallon, D Marriott, A Carr, DA Cooper, S Emery HIV medicine 7 (2), 105-111, 2006 | 118 | 2006 |
| Does choice of combination antiretroviral therapy (cART) alter changes in cerebral function testing after 48 weeks in treatment-naive, HIV-1–infected individuals commencing … A Winston, C Duncombe, PCK Li, JM Gill, SJ Kerr, R Puls, K Petoumenos, ... Clinical infectious diseases 50 (6), 920-929, 2010 | 116 | 2010 |
| Do people living with HIV experience greater age advancement than their HIV-negative counterparts? D De Francesco, FW Wit, A Bürkle, S Oehlke, NA Kootstra, A Winston, ... Aids 33 (2), 259-268, 2019 | 115 | 2019 |
